[(2R)-2,5,7,8-tetramethyl-2-[(4S,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] 4-oxo-4-(4-oxobutylamino)butanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: [(2R)-2,5,7,8-tetramethyl-2-[(4S,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] 4-oxo-4-(4-oxobutylamino)butanoate
• 化学式: C₃₇H₆₁NO₅
• 分子量: 599.9
• InChiKey: LLQRPIKGRVJYCM-UBISDZRYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.8
• 重原子数：
  43
• 可旋转键数：
  21
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  81.7
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• EP2906595B1
  申请人：——

  公开号：EP2906595B1

  公开（公告）日：2017-08-16
• Functionalized Exendin-4 Derivatives
  申请人：Sanofi

  公开号：US20140206609A1

  公开（公告）日：2014-07-24

  The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
• DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS
  申请人：Sanofi

  公开号：US20140221281A1

  公开（公告）日：2014-08-07

  The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
• Exendin-4 Derivatives
  申请人：Sanofi

  公开号：US20140206608A1

  公开（公告）日：2014-07-24

  The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
• EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS
  申请人：SANOFI

  公开号：US20160220643A1

  公开（公告）日：2016-08-04

  The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.